Skip to main content

Dr. Michael M. Haddadin, MD

Medical Oncology (Medical Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
12
In the NPI registry since
2017
Medicare patients seen, 2024
121

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. What an NPI is

Education and training

  • 2017Registered with an NPI (national billing number; not a license date)

Medicare’s Care Compare data doesn’t list this clinician’s medical school. Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Medical Oncology Physician primary
    NE license 35770

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Medical Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
121
Services billed
850
Patients’ average age
70
Most frequent Medicare services, 2023
ServiceTimesPatients
Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes6917
Established patient office or other outpatient visit, 40-54 minutes2312
New patient office or other outpatient visit, 60-74 minutes1515

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 9 companies reported 27 payments worth $6,550 in total to this clinician.

By company
Syndax Pharmaceuticals, Inc.$3,046
Adaptive Biotechnologies Corporation$1,442
Celgene Corporation$1,213
Incyte Corporation$250
Geron Corporation$226
E.r. Squibb & Sons, L.l.c.$130
Sanofi US Services Inc.$125
Amgen Inc.$74.02
By type
Consulting Fee$2,780
Travel and Lodging$2,386
Food and Beverage$1,385

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Dec 4, 2025Syndax Pharmaceuticals, Inc.
Dec 4, 2025
Consulting Fee
REVUFORJ · HEMATOLOGY-ONCOLOGY
$2,780
Oct 16, 2025Celgene Corporation
Oct 16, 2025
Travel and Lodging
travel to Aurora, CO
$627
Oct 15, 2025Celgene Corporation
Oct 15, 2025
Travel and Lodging
travel to Aurora, CO
$554
Mar 5, 2025Adaptive Biotechnologies Corporation
Mar 5, 2025
Travel and Lodging
clonoSEQ · Devices · travel to Houston, TX
$483
Mar 5, 2025Adaptive Biotechnologies Corporation
Mar 5, 2025
Travel and Lodging
clonoSEQ · Devices · travel to Houston, TX
$449
Nov 4, 2025E.r. Squibb & Sons, L.l.c.
Nov 4, 2025
Travel and Lodging
travel to AURORA, CO
$96.01
Mar 5, 2025Adaptive Biotechnologies Corporation
Mar 5, 2025
Travel and Lodging
clonoSEQ · Devices · travel to Houston, TX
$86.41
Mar 5, 2025Adaptive Biotechnologies Corporation
Mar 5, 2025
Travel and Lodging
clonoSEQ · Devices · travel to Houston, TX
$57.00
Nov 4, 2025E.r. Squibb & Sons, L.l.c.
Nov 4, 2025
Travel and Lodging
travel to AURORA, CO
$33.83

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Nebraska →

Industry-funded research

Named as a principal investigator on 1 industry-funded study in 2025, from 1 company. The companies reported $95,823 in research payments for these studies, mostly to the institutions running them.

  • A Study to Evaluate the Safety and Efficacy of Axatilimab in Combination With Ruxolitinib in Participants With Newly Diagnosed Chronic Graft-Versus-Host Disease
    Incyte Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Medical Oncology clinicians in Omaha

Sources

NPI registry (CMS NPPES, November 2026; record last updated September 20, 2023), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1780105064. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.